Vistin Pharma (VISTN.OL)

Executive Summary

Vistin Pharma is a Norwegian pharmaceutical company focused on the production of Metformin Hydrochloride, the active pharmaceutical ingredient (API) for Type 2 diabetes treatment. As Europe's only dedicated metformin API manufacturer, it supplies approximately 10% of global demand, leveraging ISO 14001 and cGMP certifications to maintain high quality standards. The company benefits from a stable demand profile driven by the global diabetes epidemic, but faces pricing pressure from low-cost producers in Asia. With a market capitalization around NOK 989 million and a lean operational structure, Vistin is positioned to capitalize on supply chain shifts toward regional manufacturing. However, its narrow product focus and reliance on a single API introduce concentration risk. The company has consistently generated positive cash flows, enabling investment in capacity expansion and regulatory compliance. Looking ahead, Vistin aims to strengthen its foothold in regulated markets and explore new opportunities in contract manufacturing.

Upcoming Catalysts (preview)

• Q3 2026Completion of capacity expansion at Norwegian facility80% success
• Q1 2027FDA approval for direct metformin API supply to US market50% success
• 2026Strategic partnership for new API development or contract manufacturing40% success